Skip to main content

Table 3 Treatment effects on mean changes in Larsen and DAS28 scores in ACPA-positive and ACPA-negative RA

From: ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial

 

Time

Ciclosporin

Prednisolone

Triple vs. monotherapy

Ciclosporin

Placebo

P

Prednisolone

Placebo

P

Triple

Mono

P

Larsen

ACPA+

6

1.60 (0.37)

2.74 (0.44)

0.047

1.44 (0.22)

2.85 (0.53)

0.015

1.25 (0.28)

3.86 (0.80)

0.003

12

3.09 (0.47)

4.81 (0.61)

0.027

2.58 (0.35)

5.26 (0.67)

0.001

2.41 (0.52)

6.92 (1.10)

<0.001

18

3.97 (0.53)

6.43 (0.78)

0.010

3.79 (0.48)

6.52 (0.80)

0.004

3.20 (0.66)

8.52 (1.39)

0.001

24

4.32 (0.58)

7.53 (0.84)

0.002

4.57 (0.57)

7.15 (0.84)

0.012

3.66 (0.70)

9.58 (1.41)

<0.001

ACPA-

6

0.72 (0.30)

1.25 (0.36)

0.270

0.67 (0.29)

1.30 (0.37)

0.182

0.48 (0.35)

1.60 (0.55)

0.093

12

2.54 (1.11)

2.17 (0.59)

0.770

1.86 (0.58)

2.79 (1.04)

0.435

1.36 (0.47)

2.03 (0.66)

0.409

18

2.97 (1.30)

2.33 (0.60)

0.660

1.86 (0.56)

3.33 (1.21)

0.275

1.66 (0.64)

2.57 (0.79)

0.388

24

3.11 (1.32)

2.56 (0.61)

0.704

2.04 (0.60)

3.52 (1.22)

0.277

1.70 (0.69)

2.72 (0.77)

0.335

DAS28

ACPA+

6

-1.61 (0.12)

-1.49 (0.13)

0.488

-1.97 (0.12)

-1.13 (0.11)

<0.001

-1.98 (0.18)

-0.99 (0.17)

<0.001

12

-1.46 (0.12)

-1.19 (0.14)

0.147

-1.36 (0.13)

-1.29 (0.13)

0.716

-1.48 (0.18)

-1.14 (0.19)

0.190

18

-1.49 (0.13)

-1.36 (0.14)

0.498

-1.50 (0.14)

-1.36 (0.13)

0.479

-1.64 (0.20)

-1.37 (0.20)

0.356

24

-1.62 (0.13)

-1.38 (0.15)

0.211

-1.62 (0.14)

-1.38 (0.14)

0.203

-1.84 (0.19)

-1.36 (0.22)

0.087

ACPA-

6

-1.02 (0.21)

-1.42 (0.20)

0.173

-1.47 (0.24)

-1.00 (0.17)

0.111

-1.43 (0.33)

-1.32 (0.22)

0.792

12

-0.94 (0.21)

-1.32 (0.21)

0.209

-1.01 (0.21)

-1.25 (0.21)

0.421

-0.73 (0.33)

-1.36 (0.33)

0.186

18

-1.33 (0.24)

-1.52 (0.20)

0.552

-1.33 (0.23)

-1.51 (0.22)

0.579

-1.27 (0.37)

-1.62 (0.30)

0.462

24

-1.16 (0.22)

-1.49 (0.20)

0.256

-1.32 (0.20)

-1.34 (0.21)

0.960

-1.27 (0.32)

-1.59 (0.30)

0.464

  1. Data are mean changes (SE) unless otherwise stated; P = P-values from t-tests; Triple = triple DMARD therapy; Mono = monotherapy with methotrexate; time is in months. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count.